{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-119726","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.792175+00:00","generated_at":"2026-06-07T23:17:11.123684+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's","bullets":["First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.","Up to 5 cohorts of 8 healthy volunteers each receive a single ascending dose; 85-day study with optional Day 120 follow-up.","Initial safety and pharmacokinetic data expected in first half of 2024.","Company raised >$20M in Q3 2023 private placement to support development through clinical milestones.","CEO Gail Farfel highlights transition to clinical stage and potential differentiation from other AD treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-119726","json":"https://secwatch.observer/filing/0001104659-23-119726.json","markdown":"https://secwatch.observer/filing/0001104659-23-119726.md","text":"https://secwatch.observer/filing/0001104659-23-119726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/0001104659-23-119726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/tm2331130d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:17:11.123684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}